John S Mulvahill1, Ginger E Nicol1, David Dixon1, Eric J Lenze1, Jordan F Karp2, Charles F Reynolds2, Daniel M Blumberger3,4, Benoit H Mulsant3,4. 1. Healthy Mind Lab, Department of Psychiatry, School of Medicine, Washington University, St. Louis, Missouri. 2. School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, Canada. 4. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Abstract
BACKGROUND/ OBJECTIVES: Metabolic syndrome (MetS) is the co-occurrence of obesity and metabolic derangements. Prior research implicates MetS in prolongation of the course of depression in older adults, but its effect on antidepressant response is unknown in this population. The objective was to determine whether MetS and related metabolic dyscrasias are associated with decreased rate of remission from depression in older adults treated pharmacologically for depression. DESIGN: Secondary analysis of a randomized controlled trial. SETTING:Three academic medical centers in North America. PARTICIPANTS: Adults aged 60 and older (mean age 69.1) with major depressive disorder (MDD) (N = 435). INTERVENTION: Open-label, protocolized treatment with extended-release venlafaxine for 12 or more weeks. MEASUREMENTS: Time to remission from depression, with remission defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 10 or less at last two visits. RESULTS: Two hundred twenty-two participants (51%) met criteria for MetS at baseline; MetS was associated with greater severity (MADRS score) and chronicity of depression at baseline. Remission was achieved in 182 participants (42%). In the unadjusted analysis, MetS was associated with prolonged time to remission (hazard ratio for remission = 0.71, 95% confidence interval = 0.52-0.95), but this relationship was not significant in the adjusted model; greater number of MetS components and lower high-density lipoprotein cholesterol had similar effects. Only diastolic blood pressure (DBP) was a significant predictor of time to remission before and after adjustment, with higher DBP predicting longer time to remission. Insulin sensitivity did not predict time to remission. CONCLUSION: The presence of MetS in older adults with depression was associated with greater symptom severity and chronicity of depression, which appears to have accounted for the poorer antidepressant response observed in those with MetS. Additionally, our preliminary finding of an association between higher DBP and poorer antidepressant response bears further examination and replication.
RCT Entities:
BACKGROUND/ OBJECTIVES:Metabolic syndrome (MetS) is the co-occurrence of obesity and metabolic derangements. Prior research implicates MetS in prolongation of the course of depression in older adults, but its effect on antidepressant response is unknown in this population. The objective was to determine whether MetS and related metabolic dyscrasias are associated with decreased rate of remission from depression in older adults treated pharmacologically for depression. DESIGN: Secondary analysis of a randomized controlled trial. SETTING: Three academic medical centers in North America. PARTICIPANTS: Adults aged 60 and older (mean age 69.1) with major depressive disorder (MDD) (N = 435). INTERVENTION: Open-label, protocolized treatment with extended-release venlafaxine for 12 or more weeks. MEASUREMENTS: Time to remission from depression, with remission defined as a Montgomery-Åsberg Depression Rating Scale (MADRS) score of 10 or less at last two visits. RESULTS: Two hundred twenty-two participants (51%) met criteria for MetS at baseline; MetS was associated with greater severity (MADRS score) and chronicity of depression at baseline. Remission was achieved in 182 participants (42%). In the unadjusted analysis, MetS was associated with prolonged time to remission (hazard ratio for remission = 0.71, 95% confidence interval = 0.52-0.95), but this relationship was not significant in the adjusted model; greater number of MetS components and lower high-density lipoprotein cholesterol had similar effects. Only diastolic blood pressure (DBP) was a significant predictor of time to remission before and after adjustment, with higher DBP predicting longer time to remission. Insulin sensitivity did not predict time to remission. CONCLUSION: The presence of MetS in older adults with depression was associated with greater symptom severity and chronicity of depression, which appears to have accounted for the poorer antidepressant response observed in those with MetS. Additionally, our preliminary finding of an association between higher DBP and poorer antidepressant response bears further examination and replication.
Authors: A K B van Reedt Dortland; E J Giltay; T van Veen; F G Zitman; B W J H Penninx Journal: Acta Psychiatr Scand Date: 2010-04-26 Impact factor: 6.392
Authors: Lauren Waterman; Sarah T Stahl; Daniel J Buysse; Eric J Lenze; Daniel Blumberger; Benoit Mulsant; Meryl Butters; Marie Anne Gebara; Charles F Reynolds; Jordan F Karp Journal: Depress Anxiety Date: 2016-09-16 Impact factor: 6.505
Authors: Victoria S Marshe; Malgorzata Maciukiewicz; Soham Rej; Arun K Tiwari; Etienne Sibille; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Charles F Reynolds; James L Kennedy; Benoit H Mulsant; Daniel J Müller Journal: Am J Psychiatry Date: 2017-01-10 Impact factor: 18.112
Authors: Nicole Vogelzangs; Aartjan T F Beekman; Ingrid G Boelhouwer; Stefania Bandinelli; Yuri Milaneschi; Luigi Ferrucci; Brenda W J H Penninx Journal: J Clin Psychiatry Date: 2011-04-05 Impact factor: 4.384
Authors: Bret R Rutherford; Warren D Taylor; Patrick J Brown; Joel R Sneed; Steven P Roose Journal: J Gerontol A Biol Sci Med Sci Date: 2017-03-01 Impact factor: 6.053
Authors: R M Marijnissen; N Vogelzangs; M E Mulder; R H S van den Brink; H C Comijs; R C Oude Voshaar Journal: Psychol Med Date: 2016-12-12 Impact factor: 7.723
Authors: Bruno Agustini; Mohammadreza Mohebbi; Robyn L Woods; John J McNeil; Mark R Nelson; Raj C Shah; Anne M Murray; Michael E Ernst; Christopher M Reid; Andrew Tonkin; Jessica E Lockery; Michael Berk Journal: CNS Drugs Date: 2019-07 Impact factor: 5.749
Authors: Woo Ri Chae; Manuel Fuentes-Casañ; Felix Gutknecht; Angela Ljubez; Stefan M Gold; Katja Wingenfeld; Christian Otte Journal: Compr Psychoneuroendocrinol Date: 2021-10-23
Authors: Jordan N Kohn; Yesenia Cabrera; Stoyan Dimitrov; Nicholas Guay-Ross; Christopher Pruitt; Farah D Shaikh; Suzi Hong Journal: Int J Obes (Lond) Date: 2019-05-14 Impact factor: 5.095
Authors: Anouk E de Wit; Erik J Giltay; Marrit K de Boer; Fokko J Bosker; Roos C van der Mast; Hannie C Comijs; Richard C Oude Voshaar; Robert A Schoevers Journal: Int J Geriatr Psychiatry Date: 2019-01-03 Impact factor: 3.485
Authors: Breno S Diniz; Benoit H Mulsant; Charles F Reynolds; Daniel M Blumberger; Jordan F Karp; Meryl A Butters; Ana Paula Mendes-Silva; Erica L Vieira; George Tseng; Eric J Lenze Journal: JAMA Netw Open Date: 2022-06-01
Authors: Jennifer Voelker; Kruti Joshi; Ella Daly; Eros Papademetriou; David Rotter; John J Sheehan; Harsh Kuvadia; Xing Liu; Anandaroop Dasgupta; Ravi Potluri Journal: Brain Behav Date: 2021-01-05 Impact factor: 3.405